Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL8940280 | 0.83 | MEN1 (0.34) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL8940287 | 0.82 | MEN1 (0.33) | MEN1LMNAKMT2A | |
| SCHEMBL8191043 | 0.82 | — | — | |
| SCHEMBL28229586 | 0.79 | — | — | |
| SCHEMBL23409712 | 0.75 | CA2 (0.33) | MEN1KMT2A | |
| SCHEMBL1696966 | 0.75 | CA2 (0.33) | MEN1KMT2A | |
| SCHEMBL31474332 | 0.75 | CA2 (0.33) | MEN1KMT2A | |
| SCHEMBL23409709 | 0.75 | CA2 (0.33) | MEN1KMT2A | |
| Tromethamine SCHEMBL11629948 | 0.75 | S1PR1 (0.40) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL11630782 | 0.75 | S1PR1 (0.40) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081865-A | Evaporation boat, preparation method thereof and application of evaporation boat in preparation of current collector | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122061108-A | Evaporation boat suitable for preparing current collector, and preparation method and application thereof | 扬州纳力新材料科技股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-108341951-B | Dynamic polymer with hybrid cross-linked structure and application thereof | 厦门天策材料科技有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-114835765-B | Synthesis process of 2' -O- (2-methoxyethyl) guanosine | 奥锐特药业(天津)有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114835765-A | 2 a , Synthesis process of (E) -O- (2-methoxyethyl) guanosine | 奥锐特药业(天津)有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-1677822-A4 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1677822-A2 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1648910-A2 | ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1569695-A2 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1532160-A2 | ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2000017223-A1 | ANTISENSE MODULATION OF RhoA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0975654-A1 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0975371-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0957926-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999011820-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND QUANTITATION OF DELETION SEQUENCE OLIGONUCLEOTIDES IN SYNTHETIC OLIGONUCLEOTIDE PREPARATIONS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999009214-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999002732-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF RAS | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998046272-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998045314-A1 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |